​​

Contact SILREAL – Strategic Healthcare & Life Sciences Consulting

​

At SILREAL, we advise healthcare, pharma, biotech, medtech, and digital health companies on policy-driven market access, cross-border strategy, and regulatory execution across Europe, the United States, and China.

Our clients engage us when policy, regulation, and geopolitics directly shape commercial outcomes – from reimbursement and procurement to licensing, localization, and strategic partnerships.

If you are facing complex market entry decisions, regulatory uncertainty, or government-facing strategy in healthcare, SILREAL acts as a decision enabler and risk filter for senior leadership teams.

​

When to Contact SILREAL

You should contact SILREAL if you are:

• A pharma or biotech company planning market entry or expansion into China or Europe

• A medtech or digital health firm navigating regulatory, reimbursement, or compliance frameworks

• An investor, private equity fund, or corporate venture unit evaluating healthcare assets with policy or regulatory risk

• A government, public institution, or industry association seeking structured dialogue with international healthcare stakeholders

Typical mandates include:

• China market access strategy (pharma, medtech, digital health)

• Policy & government affairs positioning (EU, Germany, China, US)

• Regulatory pathway analysis (NMPA, EU HTA, reimbursement systems)

• Partner search and due diligence (CDMO, CRO, distributors, hospitals)

• Cross-border licensing and localization strategy

• Digital health and AI policy positioning (Germany & China)

• Healthcare investment and market intelligence

​

How We Work

SILREAL operates as a strategic advisory partner, not a generic consultancy.

We combine:

• Policy intelligence

• Regulatory expertise

• Government and institutional networks

• Commercial strategy execution

Our work typically starts with a paid strategic diagnostic, followed by either:

• A 90-day roadmap project, or

• A long-term retainer mandate (annual advisory engagement)

This structure ensures:

• Clear scope and decision outputs

• Senior-level engagement

• Direct link between policy analysis and commercial action

​

What Makes SILREAL Different

Unlike traditional consultancies or market research firms, SILREAL focuses on the intersection of policy, regulation, and market access in healthcare.

We specialize in situations where:

• Regulation determines whether a product can be sold at all

• Policy shapes pricing, reimbursement, or procurement

• Government stakeholders influence market structure

• Cross-border data, IP, or localization rules impact scalability

Our positioning is particularly strong in:

• EU ↔ China healthcare strategy

• Germany healthcare policy and digital health

• Pharma and biotech international expansion

• Healthtech and AI regulatory environments

​

Who We Typically Work With

Our clients include:

• Global pharma and biotech companies

• European and US medtech firms entering China

• Digital health and AI health startups

• Corporate strategy and BD teams

• Private equity and healthcare investors

• Public institutions and policy platforms

Engagements are usually led at:

• C-level (CEO, CFO, CSO)

• VP / Director level (Strategy, Market Access, BD, Regulatory Affairs)

​

Start a Strategic Conversation

To ensure relevance and efficiency, we prioritize inquiries from organizations that:

• Operate in healthcare or life sciences

• Have cross-border strategic questions

• Are evaluating regulatory, policy, or market access decisions

• Seek senior-level advisory support

Initial conversations are used to assess:

• Strategic context

• Regulatory complexity

• Commercial relevance

• Fit for advisory engagement

If aligned, we will propose a structured paid entry engagement.​